Front Endocrinol (Lausanne)
August 2025
Objective: This study aimed to investigate the risk factors associated with renal impairment among patients diagnosed with primary aldosteronism (PA).
Methods: This study enrolled 147 PA patients who were initially classified into hypokalemic (n=56) and normokalemic (n=91) groups according to serum potassium levels, followed by subgroup stratification using combined adrenal venous sampling (AVS) and computed tomography (CT) diagnostic data. For comparison, 280 patients diagnosed with essential hypertension (EH) served as the control group.
Endocr Metab Immune Disord Drug Targets
February 2025
Objective: Primary aldosteronism (PA) is the most common secondary hypertension. In this study, we performed the pathway enrichment analysis based on metabolomics and transcriptomic data to find the metabolic perturbations in PA, which could provide new targets for PA and further understand the biology of PA.
Methods: 24 PA patients and 24 healthy adults served as the control group in this study.
J Clin Hypertens (Greenwich)
July 2024
This research examines the association between blood pressure variability (BPV) and renal damage in a cohort of 129 primary aldosteronism (PA) patients, employing ambulatory blood pressure monitoring (ABPM) for comparative analysis with individuals diagnosed with essential hypertension (EH). The study reveals that PA patients exhibited significantly elevated levels of cystatin C and urine microalbumin/creatinine ratio (UACR). Additionally, a higher prevalence of non-dipping blood pressure patterns in PA patients suggests an increased risk of circadian blood pressure regulation disturbances.
View Article and Find Full Text PDF